Ludwig Enterprises LUDG

OTC LUDG
$0.01 -0.01 (-50.00%)
At close: Aug 18, 2026 · 4:00 PM UTC
Financial Ratios
Market Cap1.68 Mn
P/E-1.14
Div. Yield0.00
Total Debt (Qtr)1.37 Mn
Add ratio to table…

About

Ludwig Enterprises, Inc. is an early stage genomic technology company focused on developing screening tests for inflammation related chronic diseases, including cancers. The company utilizes messenger RNA biomarkers, proprietary machine learning algorithms, and at home cheek swab collection kits to enable early detection of disease and support personalized treatment decisions. Ludwig Enterprises, Inc. expects to generate revenue primarily through the commercialization of…

Read more ↓
Sectors: Healthcare · Technology Sector rationale The company's primary revenue model is based on the commercialization of Laboratory Developed Tests (LDTs) for cancer screening, including the sale of collection kits and laboratory analysis services, which falls under Diagnostic Equipment or Healthcare Services. A secondary sector of Technology is justified because the company explicitly generates revenue through the licensing of its proprietary machine learning algorithms to partner laboratories. Industries: Diagnostic Labs Healthcare Primary Ludwig Enterprises generates revenue through laboratory analysis services for its Laboratory Developed Tests, such as the Revealia™ Breast test. The company provides clinical diagnostic testing services using mRNA biomarkers to detect inflammation-related chronic diseases and cancers. Healthcare IT Technology Secondary The company licenses its proprietary machine learning algorithms to partner laboratories, which constitutes a standalone software revenue stream for life sciences operations. Diagnostic Equipment Healthcare Secondary The company sells at-home cheek swab collection kits, which are the physical diagnostic tools required to perform its proprietary mRNA-based tests. Classified using BQ-MICS CIK: 0001960262

Peer Comparison

Companies in the Medical Devices
S.No. Ticker Company Market CapP/EP/STotal Debt (Qtr)
1 ABT Abbott Laboratories 196.58 Bn36.244.2232.61 Bn
2 SYK Stryker Corp 127.35 Bn34.154.9314.94 Bn
3 MDT Medtronic plc 118.25 Bn24.443.2527.96 Bn
4 BSX Boston Scientific Corp 74.32 Bn20.223.5412.62 Bn
5 EW Edwards Lifesciences Corp 52.61 Bn2,104.558.080.60 Bn
6 DXCM Dexcom Inc 34.26 Bn34.276.90-
7 GEHC GE HealthCare Technologies Inc. 32.92 Bn16.051.5510.10 Bn
8 SNN Smith & Nephew Plc 26.16 Bn156.664.313.21 Bn